Ann: FDA allows Veyonda Pre-IND Submission for COVID-19, page-16

Ind are not significant, they are necessary to begin a trial and by judging Nox performance on starting phase one trial I have no doubt you will be able to notch up another one. But equally judging on past performance and promised milestones the companies ability to follow through to a phase II trial is woeful. Why because they are undisciplined and keep changing priority, or according to your own presentations horses. Would you like me to give you a blow by blow of company presentation quotes that have never eventuated thus far or changed focus.